Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists.

J Surg Oncol · Jan 2021 · Review

Callegaro D, Raut CP, Keung EZ, Kim T, Le Pechoux C, Martin-Broto J, et al.

Department of Surgery, University of Toronto, Toronto, Canada

Orthopaedic Oncology

SUMMARY — THE REDUCTIONEvidence-based review giving surgical oncologists a framework to adapt treatment of GIST, extremity/truncal sarcoma, and retroperitoneal sarcoma when COVID-19 limits access to surgery.
Abstract, as published

The coronavirus disease-2019 (COVID-19) pandemic is deeply impacting the accessibility of cancer patients to surgery. In resource-limited conditions, the standard of care might not be deliverable, but evidence to support alternative management strategies often exists. By revisiting available treatment options, this review provides surgical oncologists with an evidence-based framework for treating patients with gastrointestinal stromal tumor, extremity/truncal soft tissue sarcoma, and retroperitoneal sarcoma to rapidly adapt their decision-making to the constant evolution of the COVID-19 pandemic.

Featured in the 2026-10-26 issue.

← Incidence, consequences and treatment of bone metastases in b…Emerging Concepts in Periprosthetic Joint Infection Research:… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.